Ahmed A El-Shenawy

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Ahmed A El-Shenawy, Mahmoud M A Elsayed, Gamal M K Atwa, Mohammad A S Abourehab, Mohamed S Mohamed, Mohammed M Ghoneim, Reda A Mahmoud, Shereen A Sabry, Walid Anwar, Mohamed El Sherbiny, Yasser A Hassan, Amany Belal, Abd El Hakim Ramadan
Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer. Pharmaceutics 15 (2) (2023)
Ahmed A El-Shenawy, Mahmoud M A Elsayed, Gamal M K Atwa, Mohammad A S Abourehab, Mohamed S Mohamed, Mohammed M Ghoneim, Reda A Mahmoud, Shereen A Sabry, Walid Anwar, Mohamed El Sherbiny, Yasser A Hassan, Amany Belal, Abd El Hakim Ramadan
Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer. Pharmaceutics 15 (2) (2023)
Ahmed A El-Shenawy, Mahmoud M A Elsayed, Gamal M K Atwa, Mohammad A S Abourehab, Mohamed S Mohamed, Mohammed M Ghoneim, Reda A Mahmoud, Shereen A Sabry, Walid Anwar, Mohamed El Sherbiny, Yasser A Hassan, Amany Belal, Abd El Hakim Ramadan
Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer. Pharmaceutics 15 (2) (2023)
Ahmed A El-Shenawy, Mahmoud M A Elsayed, Gamal M K Atwa, Mohammad A S Abourehab, Mohamed S Mohamed, Mohammed M Ghoneim, Reda A Mahmoud, Shereen A Sabry, Walid Anwar, Mohamed El Sherbiny, Yasser A Hassan, Amany Belal, Abd El Hakim Ramadan
Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer. Pharmaceutics 15 (2) (2023)
Mahmoud M A Elsayed, Moustafa O Aboelez, Mohamed S Mohamed, Reda A Mahmoud, Ahmed A El-Shenawy, Essam A Mahmoud, Ahmed Ali Al-Karmalawy, Eman Y Santali, Sameer Alshehri, Mahmoud Elkot Mostafa Elsadek, Mohamed A El Hamd, Abd El Hakim Ramadan
Tailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Associated with Hypertension: A Preclinical Study. Pharmaceutics 14 (8) (2022)